STOCK TITAN

Sharps Technology Inc. - STSS STOCK NEWS

Welcome to our dedicated page for Sharps Technology news (Ticker: STSS), a resource for investors and traders seeking the latest updates and insights on Sharps Technology stock.

Sharps Technology Inc. (NASDAQ: STSS) is an innovative medical device and pharmaceutical packaging company specializing in the development and manufacturing of ultra-low waste, smart safety syringes. The company’s product lines, which include Sharps Provensa, SecurGard, and SoloGard, are designed to eliminate potentially infectious needlestick injuries and reduce waste, making drug delivery safer and more efficient.

Sharps Technology, headquartered in New York, operates a state-of-the-art manufacturing facility in Hungary and has plans to expand its operations in the United States. The company recently entered into a significant partnership with Roncadelle Operations, an Italian-based leader in the development of drug delivery devices. This partnership aims to broaden Sharps' market reach into Europe, the Middle East, Africa, and Asia-Pacific regions while allowing Roncadelle to penetrate the North and Latin American markets. The companies will collaboratively sell and distribute each other’s products, including prefilled syringes, needle guard systems, auto-injectors, and injector pen devices.

One of Sharps Technology’s latest achievements includes a $200 million Sales Agreement with Nephron Pharmaceuticals, along with the acquisition of the InjectEZ syringe manufacturing facility in South Carolina. This move will make Sharps the first dedicated polymer prefillable syringe manufacturer in North America, with plans to begin product deliveries by the second quarter of 2025. The facility will produce specialized cyclic olefin copolymer (COC) prefillable syringes, addressing the growing demand for safer, more efficient drug delivery solutions.

The company’s commitment to innovation is further highlighted by its SecureGard and SoloGard syringes, which feature active safety mechanisms and WHO-accredited reuse prevention measures to protect healthcare workers and patients. Sharps is also working on expanding its product line with new technologies such as prefilled syringes, needle guard systems, auto-injectors, and injector pen devices. These efforts align with the recent FDA guidelines encouraging healthcare providers to move away from Chinese-manufactured syringes due to safety concerns.

Sharps Technology is poised for significant revenue growth and market expansion, driven by its strategic partnerships, innovative products, and robust manufacturing capabilities. For more information, please visit www.sharpstechnology.com.

Rhea-AI Summary

Sharps Technology (NASDAQ: STSS) has announced a one-for-22 reverse stock split of its common stock, effective October 15, 2024, at 11:59 PM Eastern Time. The company's stock is expected to begin trading on a post-split basis on October 16, 2024, under the same symbol 'STSS' on the Nasdaq Capital Market. This move is primarily aimed at bringing Sharps into compliance with Nasdaq's minimum bid price requirement.

The reverse split will reduce the number of outstanding common shares from approximately 39.5 million to 1.8 million. It will affect all issued and outstanding shares, as well as outstanding options, restricted stock awards, warrants, and other securities. The authorized number of shares and par value will remain unchanged. No fractional shares will be issued, with stockholders entitled to receive the number of shares rounded up to the next whole number.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
-
Rhea-AI Summary

Sharps Technology (NASDAQ: STSS) is urging shareholders to vote in favor of a reverse stock split proposal before the special meeting on October 7, 2024. The company needs to regain compliance with NASDAQ's minimum bid price requirement to maintain its listing. The Board of Directors has recommended a reverse split range of 1-for-8 up to 1-for-22.

CEO Robert M. Hayes emphasized the importance of this vote to preserve investments and enable the company to execute its business plan. Without approval, Sharps Technology expects to be delisted from NASDAQ in the near future, which could adversely affect stock value and trading volume.

Shareholders of record as of August 13, 2024, are eligible to vote. The company encourages all shareholders to vote 'FOR' the proposal to help maintain NASDAQ compliance, ensure easier trading, and provide better access to capital for growth strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.58%
Tags
none
-
Rhea-AI Summary

Aegis Capital Corp. has successfully acted as the Exclusive Placement Agent for a $3.5 Million Bridge Financing for Sharps Technology, Inc. (NASDAQ:STSS). This significant financial transaction took place on September 27, 2024 in New York, NY. The bridge financing represents a important capital injection for Sharps Technology, a company listed on the NASDAQ stock exchange under the ticker symbol STSS.

Bridge financing is typically a short-term loan used to cover immediate costs until a company can secure longer-term funding or complete a specific transaction. This $3.5 million financing could provide Sharps Technology with essential working capital or support strategic initiatives in the near term.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
none
Rhea-AI Summary

Sharps Technology, Inc. (NASDAQ: STSS) has successfully closed a $3.5 million bridge financing through a private placement of securities. The transaction, which concluded on September 24, 2024, involved the sale of $4,375,000 in principal amount of secured notes and 5,700,006 shares of common stock. For every $1,000 invested, purchasers received $1,250 in notes and 1,628.57 shares of common stock.

The company plans to use the net proceeds for general corporate purposes and working capital. Aegis Capital Corp. acted as the exclusive placement agent, with legal representation provided by Sichenzia Ross Ference Carmel LLP for Sharps Technology and Kaufman & Canoles, P.C. for Aegis Capital Corp.

As part of the agreement, Sharps Technology will file registration statements with the SEC to cover the resale of the common stock. The securities were offered only to accredited investors and have not been registered under the Securities Act of 1933.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
none
-
Rhea-AI Summary

Sharps Technology, Inc. (NASDAQ: STSS) has announced a $3.5 million secured bridge loan financing with institutional investors. The deal involves the sale of approximately $3.5 million in securities, with purchasers receiving $1,250 in aggregate principal amount of secured notes and 1,628.57 shares of common stock or pre-funded warrants for every $1,000 invested. This translates to $4,375,000 in principal amount of notes and 5,700,006 shares of common stock.

The transaction is expected to close on September 23, 2024. Aegis Capital Corp. is acting as the Exclusive Placement Agent. The company plans to use the net proceeds for general corporate purposes and working capital. The securities are being sold in a private placement to accredited investors and have not been registered under the Securities Act of 1933.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.81%
Tags
none
-
Rhea-AI Summary

Sharps Technology (NASDAQ: STSS) has secured approval from Nasdaq to maintain its listing, subject to specific conditions. The company received a Determination Letter on September 9, 2024, following an August 13 hearing where it presented its compliance plan to address a bid price deficiency. Sharps Technology had previously obtained shareholder approval for a reverse split at a ratio of up to 1:8. However, due to a proposed new Exchange rule, the company now seeks approval for a higher ratio reverse split to improve long-term compliance with the bid price rule.

The Nasdaq Hearings Panel has granted Sharps Technology a brief exception period to complete the reverse split and cure its bid price deficiency. The company expects to regain compliance within this period.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
none
Rhea-AI Summary

Sharps Technology (NASDAQ: STSS and STSSW) has entered into a transformative five-year sales agreement with a prominent U.S.-based medical products company to supply 10mL SoloGard syringes from its EU facility. This deal is valued at over $50 million and fully utilizes the current production capacity of the Hungary plant.

The agreement follows successful evaluations amid FDA recalls and tariffs on Chinese syringes. It marks a significant milestone, exceeding commitments made in a June 2022 shareholder letter and laying a foundation for future expansion. Initial shipments are slated for November 2024, with a phased ramp-up in 2025. The deal ensures Sharps' products meet growing industry demand driven by diverse therapeutic needs and regulatory challenges facing Chinese suppliers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.47%
Tags
none
-
Rhea-AI Summary

Sharps Technology's CEO, Robert Hayes, has issued a letter urging shareholders to vote on three critical proposals by July 12, 2024. The proposals include increasing the authorized shares of common stock, effectuating a reverse stock split of up to 1-for-8 to maintain Nasdaq listing, and issuing securities at a discount of no more than 20% below the market price. The company is aggressively pursuing strategic partnerships and aims to expand manufacturing capacity in Europe and the U.S. Shareholders can vote online, by phone, or during the Special Meeting on July 15, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
Rhea-AI Summary

Sharps Technology has received purchase orders for 1 million SecureGard syringes from a Swiss-based provider of injectable therapies. The first 100,000 units will ship in late July, with the remainder delivered throughout Q3 and Q4 2024. This deal marks a significant step toward a long-term partnership, leveraging Sharps' innovative technologies to support the customer's growing product range. Sharps specializes in ultra-low waste syringe solutions designed for various therapeutic applications, including vaccines and gene therapies. The company is expanding its manufacturing capacity with a new facility in South Carolina.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
none
Rhea-AI Summary

Sharps Technology, a medical device and pharmaceutical packaging company, has issued a call to action for its shareholders ahead of a special meeting scheduled for July 15, 2024. Shareholders of record as of May 17, 2024, are eligible to vote on three key proposals. These proposals include increasing the authorized number of shares, potentially effectuating a reverse stock split, and issuing securities in non-public offerings at a discount not exceeding 20% of the market price. The final vote deadline is July 12, 2024, at 11:59 p.m. ET. The Board of Directors emphasizes that these proposals are important for the company’s future operations and maintaining its Nasdaq listing. Voting can be done online, by phone, or during the virtual special meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
none

FAQ

What is the current stock price of Sharps Technology (STSS)?

The current stock price of Sharps Technology (STSS) is $2.92 as of November 6, 2024.

What is the market cap of Sharps Technology (STSS)?

The market cap of Sharps Technology (STSS) is approximately 5.5M.

What products does Sharps Technology offer?

Sharps Technology offers ultra-low waste, smart safety syringes such as Sharps Provensa, SecurGard, and SoloGard, designed to eliminate needlestick injuries and reduce waste.

What recent partnership has Sharps Technology entered into?

Sharps Technology has partnered with Roncadelle Operations to expand their market reach globally and collaboratively sell and distribute each other’s products.

What is significant about the $200 million Sales Agreement?

The $200 million Sales Agreement with Nephron Pharmaceuticals includes the acquisition of the InjectEZ syringe manufacturing facility, making Sharps the first dedicated polymer prefillable syringe manufacturer in North America.

Where are Sharps Technology’s manufacturing facilities located?

Sharps Technology has a state-of-the-art manufacturing facility in Hungary and is expanding its operations with a new facility in South Carolina, USA.

What are Sharps Technology’s core innovations?

Sharps Technology focuses on smart safety syringes with features like active safety mechanisms and WHO-accredited reuse prevention measures, aimed at making drug delivery safer and more efficient.

How does Sharps Technology contribute to healthcare safety?

Sharps Technology’s products, such as SecureGard and SoloGard syringes, protect healthcare workers from needlestick injuries and patients from the dangers of needle reuse.

What future plans does Sharps Technology have for product development?

Sharps Technology plans to develop new drug delivery technologies including prefilled syringes, needle guard systems, auto-injectors, and injector pen devices.

Why is the partnership with Roncadelle Operations important?

The partnership with Roncadelle Operations enhances Sharps Technology's access to global healthcare markets and enables them to offer a broader range of drug delivery solutions.

What regulatory standards do Sharps Technology's products meet?

Sharps Technology’s manufacturing facility in Hungary is FDA and ISO registered, CE-Mark and WHO accredited, ensuring high-quality and safe medical devices.

How does the FDA’s recent safety communication impact Sharps Technology?

The FDA's safety communication advises against using syringes manufactured in China, which positions Sharps Technology to meet the increased demand for safer, U.S. and European-manufactured syringes.

Sharps Technology Inc.

Nasdaq:STSS

STSS Rankings

STSS Stock Data

5.52M
1.80M
3.37%
3.7%
2.8%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
MELVILLE